Viatris Reports Third-Quarter 2026 Financial Results

Viatris reported Q3 2026 revenue of $3.75 billion, essentially flat year over year; adjusted EBITDA rose 4% to $1.20 billion and adjusted EPS increased 6% to $0.71, while GAAP net loss widened to $325 million, primarily because of a higher income tax provision. The company raised 2026 guidance midpoints to $14.8 billion in revenue, $4.50 billion in adjusted EBITDA, and $2.60 in adjusted EPS, excluding any Pacira contribution. Viatris agreed to acquire Pacira for $36.50 per share, or $1.65 billion in equity value, and returned approximately $717 million to shareholders year to date. Separately, it expects Nashik facility supply constraints to reduce revenue by approximately $100 million in Q4 2026; production is expected to resume in Q1 2027.

Analysis

The quality of the guidance raise matters more than its headline: revenue midpoint rose only $50 million, versus $100 million for adjusted EBITDA, EPS and adjusted free cash flow. That points to mix and cost execution—not a broad demand inflection—as the near-term earnings driver. The counterweight is cash-flow normalization: the company’s adjusted FCF outlook adds back roughly $600 million of transaction and restructuring costs, so reported cash generation is the better test of deleveraging and buyback capacity.

The Nashik shutdown is a supply, not demand, shock: the stated revenue drag is expected to persist through Q4, with production resumption only targeted for Q1 2027. Restart timing and customer recapture matter more than the initial lost sales; prolonged remediation could hand share to alternative generic suppliers and turn a temporary shortfall into lasting displacement. Regionally, Greater China growth is carrying the top line while Europe and Emerging Markets remain constrained, leaving consolidated growth exposed to a narrower set of drivers.

Pacira adds a potentially higher-growth branded pain platform, but the announced cash purchase price does not itself establish value creation. Viatris excludes Pacira from guidance, and integration, commercial execution and cash costs are the key 6–18 month tests. The near-term contrarian risk is treating adjusted EPS/EBITDA growth as evidence of a durable organic re-rating: flat quarterly revenue, recurring adjustments and supply issues argue for a restrained multiple until underlying growth broadens.

Key Decisions for Investors

• VTRS: Maintain a cautious, event-driven long bias rather than chase the guidance raise. Reassess after the earnings call for detail on organic product growth, Nashik remediation and cash costs; the thesis improves if reported operating cash flow supports debt reduction and repurchases without further exclusions.
• Use Nashik as the key 1–3 month falsification test: monitor the estimated Q4 revenue impact against the stated roughly $100 million and verify a credible Q1 2027 restart. A larger shortfall, further production delay or evidence of customer switching would weaken the VTRS thesis and benefit competing generic suppliers.
• PCRX: Treat the $36.50 cash offer as a merger-arbitrage watch, not a standalone long recommendation without the live share price and deal terms. Compare the market-to-offer spread with expected time to close and break risk; avoid entry if the spread does not compensate for regulatory, financing or closing-delay risk.
• For VTRS, track the bridge from adjusted to reported FCF and whether transaction/restructuring cash costs trend below the roughly $600 million full-year estimate. Persistent exclusions or leverage moving above the reported 2.9x level would challenge the capital-return and acquisition-capacity narrative.